Clinical Research Studies

Clinical trials and research studies are extremely important to our mission of finding better treatment options and a cure. Clinical trials can improve the quality of life of patients and help new and better therapies become available.  Additionally, participating in a clinical trial can give access to innovative treatment options and

access to expert care.

Whether you’re looking for a new experimental drug to try, or you simply want to help advance the science of Nephrotic Syndrome, there are many clinical research options. Ask your doctor and learn more about the benefits and risks of participating in Clinical Research.

Still want more information about clinical trials? Check out these debunked trial myths. 

 

---

Ongoing Clinical Trials in The US

DISCOVERY –Phase 2 Clinical Trial of APL-2 Therapy in Patients with IgAN, LN, Primary MN, and C3G.

• DISCOVERY is a Phase 2 study testing the safety and biologic activity of APL-2 therapy. Patients that enroll in the study will participate for 1 year, which includes a screening period, 16 weeks of treatment, and 24 weeks of follow-up appointments.
• Learn more about this clinical trial

FIRSTx – A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)

• FIRSTx is a Phase 2 study testing the safety and effectiveness of an investigational drug called CXA-10 designed to treat FSGS without steroids. This study will see if CXA-10 can reduce proteinuria while maintaining stable kidney function in people with FSGS.
• Learn more about this clinical trial

Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)

• The purpose of this study is evaluate if abatacept is effective and safe in decreasing the level of protein loss in the urine in patients with excessive loss of protein in the urine (nephrotic syndrome) due to either focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD). Candidates must have a prior kidney biopsy with either diagnosis.
• Learn more about this clinical trial

PHOENIX- A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases

• PHOENIX is a multi-center, open-label Phase 2 trial evaluating the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with the following rare chronic kidney diseases (CKD): CKD associated with type 1 diabetes (T1D), IgA nephropathy (IgAN), focal segmental glomerulosclerosis (FSGS), and autosomal dominant polycystic kidney disease (ADPKD). Approximately 100 patients will enroll in the trial at research centers across the United States.
• Learn more about this clinical trial

Study of Sparsentan in FSGS (DUPLEX)

• The investigational drug (sparsentan) is a dual acting angiotensin receptor blocker and endothelin receptor agonist. The active control is irbesartan. This is a randomized, multicenter, double-blind, parallel, active-control study. Approximately 300 patients aged 8 to 75 years (inclusive) will be enrolled in the study. The study will be conducted in approximately 150 study centers, globally.
• Learn more about this clinical trial

The PODO Trial: Trial to Evaluate PF-06730512 in Adults with FSGS

• The purpose of this Phase 2 adaptive study is to evaluate PF-06730512 following multiple intravenous infusions in adult patients with primary FSGS.
• Learn more about this clinical trial

Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic FSGS (The PODOCYTE Study)

• The purpose of the study is to determine whether H.P. Acthar® Gel (repository corticotropin injection) is helpful for adult patients with FSGS who still have an abnormal amount of protein in their urine, despite prior treatment.
• Learn more about this clinical trial

A Study of CCX140-B in Subjects with FSGS

• The aim of this study is to evaluate the effect of treatment with CCX140-B in patients with focal segmental glomerulosclerosis on urinary protein excretion, which will be measured by changes in UPCR.
• Learn more about this clinical trial

 

Click Here for a Full List of Ongoing Clinical Trials

Use the trial finder below to find more trials that you may be eligible for

 

---

---

NephCure does not endorse participation in any specific clinical study. Individuals should consult with their physician or health care provider to discuss the benefits & risk of enrolling in a clinical trial.

Save